

## ASX ANNOUNCEMENT

2 April 2025

# French medicinal cannabis legislation defined

- French Government notifies European Commission of medicinal cannabis legal framework setting in motion full market legalisation
- Medicinal cannabis to be fully reimbursed through health insurance
- Transition period extended to 31 March 2026 with LGP continuing to supply product at full price
- LGP strategically positioned as one of only two authorised suppliers currently in France



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") welcomes the latest advancements in France's medicinal cannabis regulatory framework, which mark a significant milestone in the country's path to full legalisation. The French Government has formally notified the European Commission of the legal texts that define the production and market authorisation framework for medicinal cannabis. This critical step establishes the pathway for regulatory approval and structured market access.

Under the new framework, all medicinal cannabis products will require a Common Technical Document (CTD) submission for market authorisation, ensuring stringent regulatory oversight. Given the significant information and data required for a CTD, the number of company's entering the French market will be limited and the transition period has been extended to 31 March 2026 during which time LGP will continue to be one of only two company's supplying products at full price.

## LGP's Strategic Positioning

LGP is currently the most well-known medicinal cannabis company in France, having supplied into the French market since March 2021 and being one of only two authorised manufacturers under the current framework. Leveraging its extensive experience and strong partnerships with French distributors, healthcare providers, and regulatory authorities, LGP is well-positioned to capitalise on the evolving market landscape.



The regulatory clarity provided by the latest notification strengthens France's role as a key market for medicinal cannabis in Europe, with a total addressable market estimated at €5.6 billion (A\$9.7 billion). LGP continues to engage proactively with regulators and industry partners to facilitate a seamless transition into the fully legalised market.

This development underscores LGP's long-term strategic vision for France and reaffirms its commitment to supplying high-quality medicinal cannabis products to patients in need.

ENDS  
BY ORDER OF THE BOARD



**Alistair Warren**  
Company Secretary

For further information please contact:

**Alistair Warren**  
**Company Secretary**  
Little Green Pharma  
E: [cosec@lgp.global](mailto:cosec@lgp.global)  
T: +618 6280 0050

**Paul Long**  
**Managing Director**  
Little Green Pharma  
E: [p.long@lgp.global](mailto:p.long@lgp.global)  
T: +618 6280 0050



## About Little Green Pharma and Reset Mind Sciences

Little Green Pharma Group is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing, distribution and clinical services.

The Company has three global production sites for the manufacture of its own-branded and white-label ranges of medicinal cannabis and psychedelic products, being a Danish glasshouse facility and West Australian indoor craft production facility with a combined nameplate capacity of 30 tonnes of cannabis biomass per annum, and a combined psychedelics clinic, head office and therapeutic goods manufacturing facility located in Western Australia.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets and delivers psychedelic assisted psychotherapy services via its wholly-owned Reset Mind Sciences business.

The Company has a strong focus on patient access in global medicinal cannabis markets and the Australian psychedelic market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com) and Reset Mind Sciences: <https://www.resetmind.com.au/>

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint

To easily update your communication preferences, visit: [www.investorcentre.com/au](http://www.investorcentre.com/au)

## LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here:  
<https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>